Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2909 studies found for:    "Carcinoma, Non-Small-Cell Lung"
Show Display Options
RSS Create an RSS feed from your search for:
"Carcinoma, Non-Small-Cell Lung"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer
Conditions: Non-Small-Cell Lung Cancer Stage IIIB;   Non-Small-Cell Lung Cancer Stage IV;   Non-Small-Cell Lung Cancer Metastatic;   Carcinoma, Non-Small-Cell Lung;   Non-Small Cell Lung Cancer;   Non-Small-Cell Lung Carcinoma;   Nonsmall Cell Lung Cancer
Interventions: Biological: bavituximab;   Drug: Docetaxel;   Other: Placebo (for bavituximab)
2 Completed Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer
Conditions: Non-Small-Cell Lung Carcinoma;   Carcinoma, Non-Small Cell Lung;   Lung Neoplasms
Intervention: Drug: EKB-569
3 Active, not recruiting Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Conditions: Carcinoma, Non-Small-Cell Lung;   Non-Small Cell Lung Cancer
Interventions: Drug: CC-223, erlotinib;   Drug: CC-223, oral azacitidine
4 Completed Pharmacogenomic Study Realized on "Non-small Cell Lung Carcinoma"
Condition: Carcinoma, Non-Small-Cell Lung
Intervention:
5 Completed Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: SGN-15;   Drug: Docetaxel
6 Not yet recruiting Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer
Conditions: Carcinoma, Non-Small-Cell Lung;   Non-Small Cell Lung Cancer;   Nonsmall Cell Lung Cancer
Intervention: Drug: Nintedanib
7 Terminated Sorafenib in Resected Non-small Cell Lung Carcinoma
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Sorafenib
8 Recruiting Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib Hydrochloride;   Other: Placebo;   Other: Laboratory Biomarker Analysis
9 Completed An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
Conditions: Carcinoma, Non-Small-Cell Lung;   Neoplasm Metastasis
Intervention: Drug: Cetuximab
10 Completed Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma
Condition: Non-Small-Cell Lung Carcinoma
Intervention: Drug: ILX651
11 Completed FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma
Condition: Non-Small Cell Lung Carcinoma
Intervention: Drug: SGN-15, Docetaxel
12 Active, not recruiting Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Drug: Gemcitabine Hydrochloride;   Drug: Vinorelbine Tartrate;   Drug: Cisplatin;   Drug: Docetaxel;   Drug: Pemetrexed Disodium;   Biological: Bevacizumab;   Other: Questionnaire Administration;   Other: Laboratory Biomarker Analysis
13 Completed FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer
Intervention: Drug: FR901228
14 Recruiting Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.
Condition: Non Small Cell Lung Carcinoma
Intervention:
15 Not yet recruiting Pazopanib in Molecularly Selected Patients With Advanced NSCLC
Conditions: Carcinoma, Non-Small Cell Lung;   Non-Small Cell Lung Cancer;   Nonsmall Cell Lung Cancer
Intervention: Drug: Pazopanib
16 Unknown  Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer
Conditions: Non Small Cell Lung Cancer;   Lung Cancer;   Stage IIIA Non Small Cell Lung Cancer;   Stage IIIB Non Small Cell Lung Cancer
Intervention: Drug: S-3304
17 Recruiting Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
Conditions: HIV Infection;   Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib Hydrochloride;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
18 Recruiting Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Azacitidine;   Drug: Entinostat;   Drug: Irinotecan Hydrochloride;   Drug: Gemcitabine Hydrochloride;   Drug: Docetaxel;   Drug: Pemetrexed Disodium;   Other: Laboratory Biomarker Analysis
19 Recruiting Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
Conditions: Non-small Cell Lung Cancer;   Advanced Non-small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Hydroxychloroquine;   Drug: Bevacizumab
20 Terminated Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy
Conditions: Carcinoma, Non-small Cell Lung;   Lung Cancer
Intervention: Drug: Satraplatin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years